Frontiers in Psychiatry,
Journal Year:
2024,
Volume and Issue:
15
Published: Oct. 30, 2024
Psilocybin,
a
psychoactive
substance,
has
recently
garnered
attention
for
its
high
therapeutic
potential
in
psychiatry.
In
this
study,
we
investigated
the
multifaceted
aspects
of
psilocybin,
highlighting
chemical
properties,
mechanisms
action,
and
burgeoning
role
psychiatric
treatment.
Furthermore,
examined
clinical
applications
benefits
psilocybin
treatment
various
mental
health
disorders,
supported
by
accumulating
evidence.
This
review
aims
to
deepen
our
understanding
impact
elucidate
value,
propose
directions
future
research,
thereby
paving
way
integration
into
mainstream
treatments.
Psilocybin
been
shown
be
safe
trials
with
manageable
side
effects.
However,
additional
safety
measures
are
required
after
discussion,
including
dosing
protocols,
patient
monitoring,
distress
management
strategies.
Headache The Journal of Head and Face Pain,
Journal Year:
2024,
Volume and Issue:
64(10), P. 1309 - 1317
Published: Sept. 20, 2024
Abstract
Background
Short‐lasting
unilateral
neuralgiform
headache
attacks
(SUNHA)
are
trigeminal
autonomic
cephalalgias
that
feature
intense
and
recurrent
paroxysms
of
pain
symptoms.
Many
patients
left
with
debilitating
symptoms
despite
best‐available
treatment.
Psychedelics,
such
as
the
serotonin
2A
partial
agonist
psilocybin,
have
shown
promise
in
related
disorders
migraine
cluster
headache.
In
this
open‐label
phase
Ib
ascending
dose
study,
we
aimed
to
assess
effects
low‐dose
oral
psilocybin
psychological
support
six
12
chronic
SUNHA.
Study
objectives
were
determine
on
cognition,
well
safety,
tolerability,
severity
frequency.
Methods
Oral
doses
5,
7.5,
10
mg
(one
per
session;
three
dosing
sessions
total)
administered.
Cognition
was
assessed
via
Cambridge
Neuropsychological
Tests
Automated
Battery.
Headache
diaries
six‐item
Impact
Test
(HIT‐6).
Subjective
intensity
five‐Dimensional
Altered
States
Consciousness
Questionnaire
(5D‐ASC).
The
study
terminated
early
due
recruitment
difficulties;
four
enrolled,
whom
completers.
Post
hoc,
undertook
a
thematic
analysis
applicable
free‐text
clinical
trial
notes
from
subsequent
visits
(
n
=
22).
An
inductive
method
employed
establish
emergent
themes.
Results
No
significant
adverse
events
recorded.
We
unable
collect
data
planned
cognitive
function
during
acute
experience
high
ratings
subjective
(mean
5D‐ASC
scores
37.8–45.7).
impact
headaches
remained
severe
throughout
duration
(HIT‐6
mean
64.3–65.7).
There
limited
based
diaries;
however,
daily
attack
frequency
decreased
by
>50%
two
participants
at
final
follow‐up
(22.9
11.0
56.4
28.0,
respectively).
Completing
their
clinicians
recorded
“much”
(two
participants)
or
“minimal”
improvements
participant)
Clinical
Global
Impression
rating
scale.
Thematic
indicated
insights
key
features
participants’
experience;
these
included
re‐configured
relationships
pain.
Conclusion
met
difficulties
cognition
could
not
be
intensity,
likely
mediated
part
expectancy
effects.
results
provide
no
conclusive
evidence
for
use
suggest
accounting
factors
SUNHA
may
an
important
facet
British Journal of Pharmacology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 29, 2024
Abstract
Psychedelic
drugs
are
under
active
consideration
for
clinical
use
and
have
generated
significant
interest
their
potential
as
anti‐nociceptive
treatments
chronic
pain,
addressing
conditions
like
depression,
frequently
co‐morbid
with
pain.
This
review
primarily
explores
the
utility
of
preclinical
animal
models
in
investigating
psilocybin
an
agent.
Initial
studies
involving
neuropathic
inflammatory
pain
summarised,
alongside
areas
where
further
research
is
needed.
The
mechanisms
action,
including
targeting
serotonergic
pathways
through
activation
5‐HT
2A
receptors
at
both
spinal
central
levels,
well
neuroplastic
actions
that
improve
functional
connectivity
brain
regions
involved
considered.
Current
aspects
translational
from
to
patients
reviewed.
Also
discussed
psilocybin's
profile
ideal
agent,
a
wide
range
effects
against
its
associated
or
emotional
components.
Headache The Journal of Head and Face Pain,
Journal Year:
2024,
Volume and Issue:
64(6), P. 599 - 600
Published: May 8, 2024
Dr.
Sarah
M.
Bobker
volunteers
her
time
as
an
Associate
Editor
at
Headache
where
she
also
manages
the
journal's
Instagram
account
and
serves
Course
Director
for
Headache's
Assistant
Team
Program.
She
has
no
personal
or
financial
disclosures.
Frontiers in Psychiatry,
Journal Year:
2024,
Volume and Issue:
15
Published: Oct. 30, 2024
Psilocybin,
a
psychoactive
substance,
has
recently
garnered
attention
for
its
high
therapeutic
potential
in
psychiatry.
In
this
study,
we
investigated
the
multifaceted
aspects
of
psilocybin,
highlighting
chemical
properties,
mechanisms
action,
and
burgeoning
role
psychiatric
treatment.
Furthermore,
examined
clinical
applications
benefits
psilocybin
treatment
various
mental
health
disorders,
supported
by
accumulating
evidence.
This
review
aims
to
deepen
our
understanding
impact
elucidate
value,
propose
directions
future
research,
thereby
paving
way
integration
into
mainstream
treatments.
Psilocybin
been
shown
be
safe
trials
with
manageable
side
effects.
However,
additional
safety
measures
are
required
after
discussion,
including
dosing
protocols,
patient
monitoring,
distress
management
strategies.
